Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Company Profile BitVentures Ltd BVC

Technology Software - Application
BitVentures Limited a technology company, develops early-stage technology businesses. It provides client referral services to external financial product partners. The company also offers insurance products which includes life insurance products, such as individual whole life, term life, health insurance, and universal life insurance; annuity insurance products; and critical illness insurance... see more

Showcase News Releases

Showcase news

Mink Ventures Corp.
Diamond Drilling Underway at Mink Ventures' Warren Property
Pinnacle Silver and Gold Corp
Pinnacle Samples up to 17.7 g/t Gold on La Estrella Vein and Extends Strike Length of La Dura Vein, Enlarging the Footprint of the Gold-Silver System at El Potrero
BioVaxys Technology Corp.
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

More Showcase News Releases »